Citation:
Vyas, Madhusudan. (2022, July). A first NZ Study Looked at the Role of Lutetium-177-PSMA I & T in the Progression of mCRPC. Paper presented at the Auckland/Northland Branch NZIMRT, Auckland University Medical School, Auckland.
Abstract
OBJECTIVES
To assess the efficacy of Lutetium-177-PSMA-I&T therapy to palliate end stage mCRPC
To review tolerability and impact on QOL of Lutetium-177- PSMA-I&T therapy
Keywords:
New Zealand, cancer patients, prostate cancer, theranostics, radionuclide therapy, Lu-177, Lutetium-177, neuroendocrine tumours (NETs), metastatic castration-resistant prostate cancer (mCRPC), mCRPC
ANZSRC Field of Research:
3211 Oncology and carcinogenesis, 320215 Nuclear medicine
Copyright Holder:
Author
Copyright Notice:
All rights reserved
Rights:
This digital work is protected by copyright. It may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use. These documents or images may be used for research or private study purposes. Whether they can be used for any other purpose depends upon the Copyright Notice above. You will recognise the author's and publishers rights and give due acknowledgement where appropriate.
